Sciwind Biosciences has received China's National Medical Products Agency (NMPA) approval for Ecnoglutide injection for the treatment of obesity and overweight in adults.[1][7] Ecnoglutide is the world's first approved cAMP-biased GLP-1 receptor agonist that works by a unique mechanism of selectively activating the cAMP signaling pathway.[2] In clinical trials in a Chinese population, it achieved an average weight loss of 15.1% compared to placebo, and 92.8% of patients achieved clinically significant weight loss.[2][4] The drug has also been approved for the treatment of type 2 diabetes in adults, with more than 80% of patients achieving HbA1c levels below 7.0%.[4] In February 2026, Sciwind Biosciences agreed to a strategic collaboration with Pfizer to commercialize the drug in China.[4] Ecnoglutide has demonstrated a favorable safety profile and strong efficacy in multiple clinical trials.[2]